Rusan Pharma achieves GMP approvals from TGA (Australia) and ANVISA (Brazil) for its manufacturing facility in Kandla SEZ
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
The inspection scope had included six separate Biologics manufacturing units comprising of four Drug Substance and two Drug Product manufacturing plants
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
The clinical trial will be conducted at 19 sites with 10,335 participants across India
Subscribe To Our Newsletter & Stay Updated